Introduction {#section6-0004867420913118}
============

High-risk criteria for psychotic disorders ([@bibr9-0004867420913118]; [@bibr11-0004867420913118]; [@bibr12-0004867420913118]; [@bibr45-0004867420913118]; [@bibr76-0004867420913118], [@bibr78-0004867420913118]) are predicated on the presence of sub-threshold psychotic symptoms, also called psychotic experiences (PEs), and the presumption that preventing or delaying transition to a full psychotic disorder syndrome is a primary therapeutic target. However, most people with PEs never develop a psychotic disorder ([@bibr27-0004867420913118]; [@bibr39-0004867420913118]; [@bibr56-0004867420913118]), but have high clinical complexity, poor response to treatment ([@bibr57-0004867420913118]; [@bibr70-0004867420913118]; [@bibr74-0004867420913118]), sub-optimal clinical and functional outcomes, and increased risk of self-harm ([@bibr24-0004867420913118]; [@bibr25-0004867420913118]; [@bibr27-0004867420913118]; [@bibr29-0004867420913118]; [@bibr33-0004867420913118]; [@bibr75-0004867420913118]). Despite evidence of these poor outcomes, many people with PEs do not meet the increasingly high thresholds for secondary care mental health services, while in primary mental healthcare settings their PEs often go unnoticed or untreated even though their depression and anxiety scores are higher, on average, than those of individuals without PEs ([@bibr27-0004867420913118]; [@bibr56-0004867420913118]).

Research on psychological interventions for people with PEs has mainly focused on delaying or preventing transition to psychotic disorder. Despite this focus, a recent network meta-analysis of transition rates among people at high risk for psychosis found no evidence to support the effectiveness of needs-based interventions (NBIs), cognitive behavioural therapy (CBT), integrated psychological interventions, or family-focused therapy (FFT) in comparison with each other ([@bibr13-0004867420913118]). A subsequent network meta-analysis of intervention effects further found that no one specific intervention was more effective than others with regard to reducing attenuated positive psychotic symptoms ([@bibr14-0004867420913118]). Yet, [@bibr51-0004867420913118] have proposed several limitations of these reviews, citing the omission of (1) trial evidence demonstrating positive group-level effects of these interventions and (2) key clinical (e.g. depression and general psychopathology) and functional outcomes that clearly have important implications for the treatment of people with PEs.

Recent meta-analyses have left a number of key gaps concerning interventions for people with PEs that must be filled in order to ensure that treatment decisions and clinical guidelines are based on the most relevant, accurate, and up-to-date evidence available. First, most reviews have limited their focus to 'ultra-high risk' or 'clinical high risk' populations, thereby omitting people with PEs who may not have these diagnoses. Second, there is presently no meta-analytic evidence addressing the question of which psychological interventions lead to *remission* from PEs and improvement in depression, anxiety, and general functioning, all of which are important features of at-risk states for psychosis that lead to disability ([@bibr10-0004867420913118]; [@bibr23-0004867420913118]; [@bibr37-0004867420913118]). Third, the psychological intervention that has been most investigated in the context of people with PEs is CBT, while the evidence concerning alternative approaches has yet to be collated ([@bibr53-0004867420913118]). Fourth, the cost-effectiveness of achieving therapeutic targets other than transition has received little attention. Fifth, no review has set limitations for the use of antipsychotics, despite the fact that international guidelines do not generally recommend their use for people at-risk for developing psychosis ([@bibr1-0004867420913118]; [@bibr19-0004867420913118]; [@bibr50-0004867420913118]; [@bibr64-0004867420913118]). Finally, no review has aimed to illuminate the key ingredients of effective psychological interventions for this population. To address these significant gaps in the literature and to inform the development of a new therapeutic framework, we conducted a systematic review and meta-analysis that aimed to (1) synthesise evidence about the effectiveness of and economic outcomes associated with psychological interventions for people with PEs and (2) identify common components of effective interventions.

Methods {#section7-0004867420913118}
=======

This review was conducted as part of the *Tailoring evidence-based psychological therapY for People with common mental disorder including Psychotic EXperiences* (TYPPEX), a nationwide National Institute for Health Research (NIHR) Programme Grant for Applied Research (RP-PG-0616-20003) that aims to develop an effective therapeutic framework for service users with PEs in the UK Improving Access to Psychological Therapies (IAPT) primary mental healthcare setting ([www.england.nhs.uk/mental-health/adults/iapt/](http://www.england.nhs.uk/mental-health/adults/iapt/)). The programme focuses on clinical and functional outcomes *other* than transition to psychotic disorder, reflecting the low transition rate among individuals with PEs accessing primary mental healthcare services ([@bibr27-0004867420913118]; [@bibr56-0004867420913118]). The therapeutic framework will adhere to current international guidelines, which recommend psychological therapy -- but *not* antipsychotic medication -- for the treatment of individuals with PEs ([@bibr50-0004867420913118]; [@bibr64-0004867420913118]).

The protocol was registered with the International Prospective Register of Systematic Reviews (PROSPERO; [www.crd.york.ac.uk/prospero](http://www.crd.york.ac.uk/prospero)), registration number: CRD42016033869 (22 May 2018 version), and a full protocol has been published prospectively elsewhere ([@bibr66-0004867420913118]). We follow the PRISMA ([@bibr38-0004867420913118]) reporting guidelines.

Data sources and searches {#section8-0004867420913118}
-------------------------

Two research assistants (E.S. and D.R.) collaborated with medical librarians at the University of Cambridge to create the search strategy ([Supplemental Appendix A](https://journals.sagepub.com/doi/suppl/10.1177/0004867420913118)). The strategy combined terms for PEs, specific psychotic symptoms and psychological interventions, as well as database-specific subject headings. We searched MEDLINE, Embase and Health Management Information Consortium (HMIC) via Ovid; PsycINFO, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Education Resources Information Center (ERIC) and EconLit via EBSCO; British Nursing Index (BNI) via ProQuest; and all Cochrane databases from 1 January 2000 (or the earliest publication date included in the database, if after 2000) to 15 December 2018 (when we ran all searches). We additionally searched the World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) for relevant trials and Google Scholar, EThOS, and Open Grey for grey literature and dissertations. We collected additional citations through hand-searching reference lists of included publications.

Study selection {#section9-0004867420913118}
---------------

We included studies that examined any psychological intervention in adults with PEs but *not* psychotic disorders. To be included in our review, studies were required to have used the presence of PEs as the main study entry criterion. Due to the variety of terms used to represent PEs, we included populations with the following diagnoses: at-risk mental state, ultra-high risk/clinical high risk, attenuated psychosis, psychotic-like experiences, unusual experiences, sub-threshold psychosis, prodromal psychosis and schizotypal disorders. We restricted our studies to adults (operationalised as studies in which participants' mean age was ⩾16 years) to reflect the age of people attending adult mental health services (e.g. UK IAPT services).

We included all frameworks of psychological interventions provided their effects were studied *in people with PEs* (i.e. interventions did *not* need to target PEs specifically). We did not restrict intervention setting (and included online interventions). We excluded studies that combined psychological and pharmacological interventions (i.e. where medication was provided *as part of the intervention protocol*). For medication prescribed *external to the intervention*, we placed no restriction regarding the proportion of participants taking medication for depressive or anxiety disorders, but included only studies in which less than 25% of participants were prescribed antipsychotic medication. The decision to limit the proportion of the study population using antipsychotic medication aligns with international guidelines' cautions against prescribing antipsychotics for people at high-risk for developing psychosis ([@bibr1-0004867420913118]; [@bibr19-0004867420913118]; [@bibr50-0004867420913118]; [@bibr64-0004867420913118]). This exclusion criterion further ensured the review was relevant to the UK IAPT setting, where psychological interventions are the only available treatment.

Our outcomes of interest were (1) the proportion of participants who remitted from PEs (primary outcome) and (2) changes in depression, anxiety, functioning, distress, quality of life or positive/negative psychotic symptoms (secondary outcomes). We placed no restriction on which tools were used to measure any of these outcomes, so long as they were valid and reliable. We did not set an a priori inclusion criterion for how to define remission from PEs (we include in our results how each study defined/measured this outcome). In addition, we included studies that reported any of the following economic outcomes: resource use, cost, partial economic evaluations, and full economic evaluations (where full economic evaluations are those that consider both the cost and outcomes of two or more interventions in a comparative analysis and partial economic evaluations focus only on cost description, cost-outcome description or comparative cost, analysis \[[@bibr18-0004867420913118]\]). Outcomes did not need to be the primary outcome of a study to be included in our review.

We placed no restriction on study design or comparator. We chose not to limit our review to controlled trials in order to ensure that newer intervention frameworks (which may be at pilot or earlier stages) could be represented.

We reviewed studies published in any language provided they had an English abstract (no foreign language articles advanced past the title/abstract screening stage). We excluded reports published before 2000 (when the at-risk mental state became widely adopted), reports where only an abstract was available, and secondary analyses of data from the same trial (to avoid including the same data from one individual multiple times within our results).

Two reviewers (E.S. and D.R.) independently screened titles and abstracts and excluded obviously irrelevant titles. We then reviewed the full texts of potentially relevant citations against our inclusion and exclusion criteria. Disagreements were resolved by discussion, with input from a third reviewer (C.K., J.P.) as necessary.

Data extraction and quality appraisal {#section10-0004867420913118}
-------------------------------------

Three reviewers (E.S., D.R., and M.H.) designed and piloted data extraction sheets. We extracted information on study/sample characteristics, intervention components and descriptions, data for outcomes related to our primary or secondary outcomes, and data required for quality assessment (see protocol for more detail ([@bibr66-0004867420913118]). Where information was not available, we consulted study protocols and contacted study authors by email. Two reviewers independently extracted data from a subset of four papers (17%) and one reviewer extracted the rest. Both reviewers reviewed all quantitative data for each included study.

We assessed risk of bias using the Effective Public Health Practice Project's (EPHPP) Quality Assessment Tool for Quantitative Studies ([@bibr4-0004867420913118]) for all reports and additionally used the Drummond Critical Appraisal of Economic Evaluations Checklist ([@bibr17-0004867420913118]) for economic reports. Two raters (E.S. and D.R.; M.H. and S.B. for economic studies) independently assessed quality, compared ratings and resolved disagreements by discussion.

Data synthesis and analysis {#section11-0004867420913118}
---------------------------

### Meta-analysis {#section12-0004867420913118}

We analysed controlled studies through random-effects meta-analysis of standardised mean differences (SMDs) for our secondary clinical and functional outcomes (we did not have sufficient reports to perform meta-analysis for our primary outcome; see below). To combine outcomes from multiple follow-up points within individual reports, we fitted meta-analytic multilevel random-effects models via functions in the *metafor* package ([@bibr73-0004867420913118]). A relatively new methodology, multilevel meta-analysis is becoming popular in the literature ([@bibr21-0004867420913118]). The model overcomes the possibility of bias of overall effect by acknowledging that different time-points are not independent and correcting for this.

Ultimately, we conducted seven separate meta-analyses (one for each secondary outcome), separating each by the framework of the psychological intervention being investigated (as per protocol; [@bibr66-0004867420913118]). As CBT was the only intervention to be represented in more than one study, we were not able to conduct meta-analyses for the other intervention frameworks included in the review.

We separated results by comparator framework (supportive treatments \[STs\] vs treatment as usual \[TAU\]). We classified the following interventions as ST: supportive therapy, supportive counselling, non-directive reflective listening, NBI, and needs-focused intervention. The decision to group these interventions was based on similarities in their purpose and provision. We considered these interventions to have a common aim, namely, to act as non-specific active comparison groups. They further share several characteristics (e.g. warm, empathic listening and absence of active therapeutic techniques). This classification also facilitates comparison with related reviews that used similar groupings ([@bibr13-0004867420913118], [@bibr14-0004867420913118]). In reporting our results, we provide separate pooled estimates for each comparator framework (i.e. ST and TAU separately) as well as an estimate for both comparators combined (i.e. ST and TAU combined). There are clinical and statistical reasons for this decision. First, the difference between TAU and ST is not well-defined; for example, 'TAU' sometimes consisted of CBT for depression or anxiety. Second, we found no statistical evidence to indicate any meaningful difference between outcomes for these comparators. As both interpretations are valid, and to ensure our results can adequately inform clinical practice, we include both estimates.

### Sensitivity and sub-group analyses {#section13-0004867420913118}

We also conducted sensitivity analyses by including only those reports that received a global rating of 'strong' on the EPHPP tool.

No controlled clinical trials (CCTs) met inclusion criteria, and so our planned sensitivity analysis on the impact of CCTs was not possible. We had also intended to conduct sub-group analyses based on population (clinical vs non-clinical), but no studies of non-clinical populations were eligible for inclusion in the meta-analyses. Finally, we had intended to use sub-group analyses to quantitatively assess four a priori components of interest for cognitive therapy as previously highlighted in the literature: assessment of problems and goals, formulation, homework, and active change strategies ([@bibr22-0004867420913118]; [@bibr47-0004867420913118]). However, included reports did not meet our pre-specified criteria for sub-group analyses (see protocol for more detail; [@bibr66-0004867420913118]).

### Assessment of heterogeneity and meta-biases {#section14-0004867420913118}

Although we aimed to assess heterogeneity of the meta-analytic results, our estimates were unreliable due to low numbers of included reports in each meta-analysis ([@bibr15-0004867420913118]). We still report Cochran's *Q* for each meta-analysis, but interpretation needs to be cautious. For the same reason, it was not possible to perform the assessments of bias (e.g. publication bias, citation bias) specified in our protocol.

### Narrative synthesis {#section15-0004867420913118}

We use narrative synthesis ([@bibr61-0004867420913118]) to synthesise effectiveness findings and pre--post changes in our outcomes of interest from (1) controlled studies not eligible for inclusion in the meta-analyses and (2) uncontrolled studies. We furthermore narratively describe findings relating to common components of effective therapies.

### Economic analysis {#section16-0004867420913118}

We present economic studies in tables containing study characteristics and results and use a narrative approach to synthesise findings as a result of the very small number of identified studies meeting inclusion criteria for the economic component of the review. We further discuss reports in terms of quality, using the Drummond checklist ([@bibr18-0004867420913118]).

Results {#section17-0004867420913118}
=======

Search results {#section18-0004867420913118}
--------------

We identified 27 reports from 21 studies that met inclusion criteria (flowchart in [Figure 1](#fig1-0004867420913118){ref-type="fig"}; summary of studies' characteristics in [Table 1](#table1-0004867420913118){ref-type="table"}; justifications for exclusion after full-text screening in [Supplemental Appendix B](https://journals.sagepub.com/doi/suppl/10.1177/0004867420913118); summary of baseline and outcome data in [Supplemental Appendix C](https://journals.sagepub.com/doi/suppl/10.1177/0004867420913118); intervention components in [Supplemental Appendix D](https://journals.sagepub.com/doi/suppl/10.1177/0004867420913118)). Of these 27 reports, 4 reports using data from two randomised controlled trials (RCTs) included economic components that met our inclusion criteria. The interventions had diverse frameworks; while the vast majority of studies focused on variations on CBT or ST (with the latter always serving as the comparator), one study each represented strengths and mindfulness-based online social therapy, sleep CBT, mindfulness-based cognitive therapy, FFT, family psychoeducational intervention, cognitive remediation, and systemic therapy (each described below). The majority of these frameworks have been tested in the past 5 years, suggesting increased interest in new intervention frameworks for people with PEs.

###### 

Summary of studies included in the clinical effectiveness component of the review.

![](10.1177_0004867420913118-table1)

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  1st author (year)Country/study region         Outcomes of interest^1^                                                                                                                                                            Intervention frameworkComparator (if any)^2^                                                                                                                                     Study designDuration of follow-up measurement                                                                                                                   Sample size & characteristics                                                                                                                                                                                                                                                                                                                                                  Consent rateDrop-out rate                                                                                                                                   Main findings (as relevant to review aims)
  --------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  [@bibr2-0004867420913118]^36^Canada           Primary: transition to psychosisSecondary: depression, anxiety, functioning                                                                                                        CBTSupportive therapy                                                                                                                                                            Single-blind RCTPost-intervention, 6 & 12 mo. post-intervention (6, 12, 18 mo. post-baseline)                                                                   All: N=5170.1% maleCBT: N = 2766.7% male; mean age = 20.8 (SD 4.5) years; 48.1% WhiteST: N = 24 75.0% male; mean age = 21.1 (SD 3.7) years; 66.7% White                                                                                                                                                                                                                        50%45.1% (CBT: 44.4%; ST: 45.8%)                                                                                                                            Sig. improvement in positive symptoms over time for both groups (p\<0.001) but no between-group differences in change rate over time (p=0.44).No sig. between-group differences in depression; sig. improvement in ST group from baseline to 6 mo. post-baseline (p\<0.05). No sig. between-group differences in anxiety, but both groups improved over time on SIAS (p\<0.05). Significant improvement ST group on SAS between baseline and 18 mo. post-baseline (p\<0.05). No sig. between group differences or within-group time effects in negative symptoms or social functioning.

  [@bibr3-0004867420913118]^37^Australia        Acceptability, safety, social functioning                                                                                                                                          Strengths and mindfulness-based online social therapyNA                                                                                                                          Pre-post (pilot)2 mo. post-baseline                                                                                                                             N = 1421.4% male; mean age = 20.3 (SD 3.4) years                                                                                                                                                                                                                                                                                                                               ND7.1%                                                                                                                                                      Trend toward improvement in all clinical measures at 2 mo. follow-up: 42% of participants improved reliably across clinical measures; 25% showed increased depressive symptoms at follow-up (no evidence for association between system use and increased depressive symptoms). Sig. large improvement in social functioning from baseline to follow-up (d=1.83, p\<0.001) with all participants reliably improving. Sig. large increase in subjective wellbeing (d=0.75); 42% of participants improved reliably in subjective wellbeing and 33% declined in loneliness.

  [@bibr6-0004867420913118]^38^Germany          Prodromal symptoms, prevention of social decline/stagnation, and prevention or delay of transition to psychosis                                                                    CBTNA                                                                                                                                                                            Prospective pre-post designPost-intervention only                                                                                                               N = 1275.0% male; mean age = 22.9 (SD 3.6) years                                                                                                                                                                                                                                                                                                                               ND16.8%                                                                                                                                                     Sig. pre-post improvements in global psychopathology (p=0.009), social adjustment (p=0.005), basic symptoms (p=0.008), depression (p=0.009), anxiety (p=0.013), and social adjustment (p=0.005) in group who completed intervention. Depression improved from medium-severe to no longer clinically relevant; social adjustment improved from serious to mild impairment.

  [@bibr7-0004867420913118]^39^Germany          Social adjustment                                                                                                                                                                  CBTSupportive counselling (SC)                                                                                                                                                   RCTPost-intervention only                                                                                                                                       N = 113CBT: N = 5464.8% male; mean age = 25.2 (SD 5.3) yearsSC: N = 5967.8% male; mean age = 26.4 (SD 5.7) years                                                                                                                                                                                                                                                               ND40.7% (CBT: 46.3%; SC: 35.6%)                                                                                                                             No sig. between-group differences in any dimension of social adjustment. Large pre-post improvements for both CBT and SC groups. Sig. improvements for CBT group in 'work' dimension (p=0.009) and global rating (p=0.010) but not other dimensions. Sig. improvements in SC group for 'work' dimension (p=0.003), 'social activities' dimension (p=0.03), and global rating (p\<0.001).

  [@bibr8-0004867420913118]^40^UK               DSM-IV sleep disorders, insomnia, sleep quality, attenuated psychotic experiences, negative affect, quality of life                                                                Sleep CBTNA                                                                                                                                                                      A-BPost-intervention, 1 mo. post-intervention                                                                                                                   N = 1241.7% male; mean age = 18.5 (SD 1.9) years; 83.3% White                                                                                                                                                                                                                                                                                                                  100%8.3%                                                                                                                                                    Improvement across all outcome measures (depression d=0.5, stress d=0.8, anxiety d=0.2, wellbeing d=0.7, occupational and social functioning d=0.7, paranoia d=0.6, hallucinations d=0.3). Statistical significance not reported.

  [@bibr20-0004867420913118]^41^UK              Primary: depression, anxiety, distressSecondary: return to prison rates                                                                                                            CBTNA                                                                                                                                                                            Pre-postFollow-up not explicit (from paper: 'The current study was run between the end of 2011 and mid-2014; follow-up data were collected in September 2015)   N = 52100% male; mean age = 23.9 (SD 5.2) years; 38.5% White                                                                                                                                                                                                                                                                                                                   100%28.8%                                                                                                                                                   Reductions in depression (p\<0.01), anxiety (p\<0.001), and psychological distress (p\<0.002).

  [@bibr30-0004867420913118]^42^Netherlands     Primary: transition to psychosisSecondary: depression, anxiety, positive and negative symptoms, distress, social functioning                                                       CBTuhr + TAUTAU only                                                                                                                                                             Single-blind RCT3.5 years post-intervention (48 mo. post-baseline)                                                                                              N= 113CBT: N = 5650.5% male; mean age = 22.7 (SD 5.6) years; 49.5% ethnic minorityTAU: N = 5748.5% male; mean age = 22.6 (SD 5.4) years; 39.6% ethnic minority                                                                                                                                                                                                                 ND42.3%                                                                                                                                                     Proportion of participants remitting from subclinical psychotic symptoms:CBT: 45/59TAU: 37/63Remission proportion significantly higher in CBTuhr group (p=0.04).No sig. differences in psychopathology between groups (who didn't transition to psychosis). Reduced depression and anxiety scores (statistical significance not reported).

  [@bibr35-0004867420913118]^43^Germany         Basic symptoms, depression, functioning                                                                                                                                            Integrated psychological intervention (including CBT) (IPI)Supportive counselling (SC)                                                                                           RCTPost-intervention only (12 mo. post-baseline)                                                                                                                N = 91IPI: N = 4566.7% male; mean age = 24.1 (SD 4.3) yearsSC: N = 4658.7% male; mean age = 26.9 (SD 6.0) years                                                                                                                                                                                                                                                                91.1%28.9%                                                                                                                                                  No sig. differences in improvement between IPI and SC in any outcome (PANSS total, basic symptoms, depression, functioning). *For both groups combined*, significant improvement in every measure (PANSS total d=1.12, basic symptoms: d=0.76, depression symptoms d=1.07, functioning d=-0.73).

  [@bibr36-0004867420913118]^44^Spain           Frequency & anxiety/distress associated with psychotic-like experiences                                                                                                            Mindfulness-based cognitive therapy (MBCT)Video-forum viewing                                                                                                                    Quasi-RCTPost-intervention, 16 wk. post-intervention                                                                                                            N = 38MBCT: N = 1822.2% male; mean age = 21.6 (SD 3.3) yearsVideo-forum viewing: N = 2010.0% male; mean age = 21.1 (SD 1.8) years                                                                                                                                                                                                                                              NDPost-intervention: 0%; follow-up: 36.8%                                                                                                                   Sig. difference between-group difference in anxiety at post-intervention (d=0.88) and 16 wk. follow-up (d=0.91); no other sig. differences, but 'important changes' in distress, intrusive thoughts, and auditory distortions at post-intervention.

  [@bibr44-0004867420913118]^45^ Japan          Primary: total score on the PANSSSecondary: PANSS subscale scores, positive symptoms on the CAARMS, depression, anxiety, functioning, quality of life, client satisfaction         CBTNA                                                                                                                                                                            Pre-post (open-label pilot study)Post-intervention, 6 mo. post-intervention (6 & 12 mo. post-baseline)                                                          N = 1338.5% male; mean age = 18.7 (SD 3.6) years                                                                                                                                                                                                                                                                                                                               ND0%                                                                                                                                                        46.2% and 84.6% of participants had remitted from At-Risk Mental State at 6 and 12 mo. post-baseline, respectively. Sig. (p\<0.05) pre-post differences at 6 and 12 mo. post-baseline for all outcomes except PANSS negative (i.e. PANSS total, PANSS positive, PANSS global psychopathology, CAARMS positive symptoms, CAARMS suicidality & self-harm, CAARMS aggression/dangerous behaviour, depression, anxiety, functioning, and quality of life (effect sizes d=0.75-2.20). No sig. improvement in PANSS negative scores at either timepoint.

  [@bibr40-0004867420913118]^46^Multiple        Primary: transition to psychosisSecondary: general levels of psychopathology and functioning                                                                                       CBT with case management (CBCM) + placeboCBCM + poly-unsaturated fatty acids (PUFAs)                                                                                             Double-blind placebo-controlled RCTPost-intervention, 6 mo. post-intervention (6 & 12 mo. post-baseline)                                                        N = 304CBCM + placebo: N = 15140.4% male; mean age = 18.9 (SD 4.3) years; 80.1% WhiteCBCM + PUFAs: N = 15351.0% male; mean age = 19.4 (SD 4.8) years; 80.4% White                                                                                                                                                                                                              66.2%CBCM + placebo: 26.5%CBCM + PUFAS: 25.5%                                                                                                               Sig. improvement over time for CBCM participants for each measure (i.e. BPRS score, negative symptoms, mania, depression, social and occupational functioning, global functioning).

  [@bibr41-0004867420913118]^47^Australia       Primary: transition to psychosisSecondary: psychiatric symptoms, social functioning, quality of life                                                                               Cognitive therapy plus low-dose risperidone (CT + R)Cognitive therapy plus placebo (CT + PL)Supportive therapy plus placebo (ST + PL)Monitoring only (not randomised) (MON GR)   Double-blind, placebo-controlled RCTPost-intervention only (12 mo. post-baseline)                                                                               N = 115CT + R: N = 4334.9% male; mean age = 17.6 (SD 3.0) years CT + PL: N = 4438.6% male; mean age = 18.0 (SD 2.7) yearsST + PL: N = 2846.4% male; mean age = 18.8 (SD 3.7) yearsMON GR: N = 7839.7% male; mean age = 17.8 (SD 2.6) years*NB: Sample characteristics for the 62.7% of participants that remained in the study for the 12 month follow-up are not reported.*   24.8%12 mo. follow-up:CT + R: 37.2%CT + PL: 34.1% ST + PL: 32.1%                                                                                            Improvement in all measures (i.e. BPRS scores, negative symptoms, depression, global functioning, quality of life; statistical significance not reported). No sig. difference in improvement between CBT + placebo, supportive counselling + placebo, CBT + risperidone, or monitoring groups on any outcome.Z

  [@bibr42-0004867420913118]^48^Australia       Primary: transition to psychosisSecondary: depression, anxiety, psychiatric symptoms, negative psychotic symptoms, mania, quality of life, functioning                             Psychological, needs-based intervention (NBI)Specific preventive intervention (SPI) (all elements of NBI plus CBT and risperidone)                                               RCTPost-intervention, 6 mo. post-intervention (6 & 12 mo. post-baseline)                                                                                        N = 59NBI group = 2850.0% male; mean age = 20.0 (SD 3.0) yearsSPI group = 3164.5% male; mean age = 20.0 (SD 4.0) years                                                                                                                                                                                                                                                         68.1% for study participation; 43.7% for randomisationSPI: 0%NBI: ND                                                                                        Levels of all symptoms improved in NBI (BPRS score/BPRS psychotic subscore, anxiety, depression, negative symptoms, mania; statistical significance not reported); functional levels (global functioning, quality of life) were more stable.

  [@bibr48-0004867420913118]^49^UK              Primary: transition to psychosis, severity of psychotic symptoms, distress caused by psychotic symptomsSecondary: emotional dysfunction, quality of life                           Cognitive therapy + mental state monitoringMental state monitoring only                                                                                                          Single-blind RCTPost-intervention, 6 & 18 mo. post-intervention (6, 12, 24 mo. post-baseline)                                                                   N = 28862.5% male; mean age = 20.7 (SD 4.3) yearsCT + mental state monitoring: N = 14461.8% male; mean age = 20.7 (SD 4.2) yearsMental state monitoring only: N = 14463.2% male; mean age = 20.8 (SD 4.5) years                                                                                                                                                                NDCT: 6 mo. follow-up: 32.6%12 mo. follow-up: 34.0%24 mo. follow-up: 76.4%Monitoring:6 mo. follow-up: 31.3%12 mo. follow-up: 35.4%24 mo. follow-up: 78.5%   Sig. greater reduction in severity of psychotic experiences in CT group (effect size at 12 mo. post-baseline -3.67 95% CI: -6.71 to -0.64, p=0.018) but no sig. between-group difference in distress from psychotic experiences (estimated difference at 12 mo. post-baseline -3.00 95% CI: -6.95 to 0.94). No sig. between-group differences in levels of functioning, depression, social anxiety, or quality of life.

  [@bibr49-0004867420913118]^50^UK              Primary: transition to psychosisSecondary: prescription of antipsychotic medication, probable DSM-IV diagnosis from blinded consultant psychiatrist, scores on PANSS               Cognitive therapy + monitoringTAU (monitoring only)                                                                                                                              Single-blind RCTPost-intervention, 6 mo. post-intervention^3^                                                                                                   All: N = 60 (N = 58 analysed; 2 cases of psychosis at baseline)66.7% male; mean age = 22.0 (SD 4.5) yearsCT: N = 37 (N = 35 analysed) 60.0% male; median age = 20.6 (IQR 4.9) yearsTAU: N = 2383.0% male; median age - 21.5 (IQR 5.2) years                                                                                                                                    95%14%                                                                                                                                                      Sig. greater reduction of frequency positive symptoms in CT group compared with TAU (p=0.049). No sig. between-group differences in functioning or distress (but many missing 12-mo. scores).

  [@bibr51-0004867420913118]^51^Multiple        Primary: transition to psychosis, symptomatic & functional outcomeSecondary: clinical predictors of medium-term outcome                                                            CBT with case management (CBCM) + placeboCBCM + poly-unsaturated fatty acids (PUFAs)                                                                                             Double-blind placebo-controlled RCTMean = 3.4 (SD 0.9; range 1.5-5.7) years post-baseline                                                                       N = 270CBCM + placebo: N = 13740.4% male; mean age = 18.9 (SD 4.3) years; 80.1% WhiteCBCM + PUFAs: N = 13351.0% male; mean age = 19.4 (SD 4.8) years; 80.4% White*NB: characteristics of follow-up sample not given; characteristics reflect those of the original sample.*                                                                                                    66.2%11% (CBCM + placebo: 9%; CBCM + PUFAs: 13%)                                                                                                            Improvement in CBCM group for all symptom and functioning measures from baseline to medium-term follow-up (i.e. CAARMS subscales, BPRS total/psychotic subscale, anxiety, negative symptoms, mania, depression symptoms, social & occupational functioning, global functioning). Most improvement in symptom & functioning outcomes achieved by end of the intervention period (12 mo.) with only minimal improvement afterwards.

  [@bibr54-0004867420913118]^52^North America   Primary: perceived criticism (mother and child)Secondary: positive psychotic symptoms                                                                                              Family focused therapy (FFT)Family psychoeducational intervention (EC)                                                                                                           RCTPost-intervention, 6 mo. post-intervention (6 & 12 mo. post-baseline)                                                                                        N = 90FFT: N = 4658.7% male; mean age = 16.7 (SD 3.3) yearsEC: N = 4459.1% male; mean age = 17.0 (SD 3.1) years                                                                                                                                                                                                                                                                NDPost-intervention: 52% 6 mo. follow-up: 54%                                                                                                               Changes in mothers' criticism predicted youths' positive symptoms at 12 mo. post-baseline. Regression model including positive symptoms at baseline/6 mo. post-baseline, changes in maternal criticism, treatment condition, interaction of change in criticism & treatment condition, and use of antipsychotics explained 42% of variance in positive symptoms at 12 mo. post-baseline but treatment not a statistically sig. predictor in this model.

  [@bibr59-0004867420913118]^53^Australia       Primary: transition to psychosisSecondary: levels of psychopathology, general functioning                                                                                          Psychological, needs-based intervention (NBI)Specific preventive intervention (SPI) (all elements of NBI plus CBT and risperidone)                                               RCT2.5-3.5 years post-intervention (3-4 years post-recruitment)                                                                                                 N = 41NBI = 1750.0% male; mean age = 20.0 (SD 3.0) yearsSPI = 2465.0% male; mean age = 20.0 (SD 4.0) years*NB: characteristics of follow-up sample not given; characteristics reflect those of the original sample.*                                                                                                                                                           69.5% of original sample (NBI: 61%; SPI: 77%)0%                                                                                                             Sig. higher scores for mania and quality of life in NBI group as compared with baseline scores. No other sig. within-group differences between baseline and 3-4 year follow-up on any measure (i.e. anxiety, depression, BPRS, BPRS psychotic subscale, negative symptoms, functioning).

  [@bibr60-0004867420913118]^54^Canada          Primary: cognitive functionSecondary: social and role functioning                                                                                                                  An auditory processing Cognitive Remediation Therapy (the Brain Fitness Program) (CRT)Control treatment of commercially available computer games                                 Single-blind, pilot RCTPost-intervention, 6 mo. post-intervention (3 & 9 mo. post-baseline)                                                                     N = 32CRT: N = 1861.1% male; mean age = 19.7 (SD 5.7) yearsControl: N = 1471.4% male; mean age = 17.5 (SD 3.5) years                                                                                                                                                                                                                                                           NDCRT: 69.6%Control: 65%                                                                                                                                    Sig. improvements in global functioning (social scale) for CRT group from post-CRT to 9 mo. post-baseline (p\<0.05) and 'trend' (p=0.06) from baseline to 9 mo. post-baseline. No sig. within-group changes in role functioning.

  [@bibr63-0004867420913118]^55^Germany         Prodromal symptoms, global functioning, extrapyramidal side effects                                                                                                                Needs-focused intervention(NFI)Needs-focused intervention + amisulpride (NFI + AMI)                                                                                              Open-label, randomised parallel-group studyPost-intervention only (12 wk. post-baseline)                                                                        N = 124 (102 analysed)NFI: N = 59 (44 analysed)47.5% male; mean age = 25.1 (SD 6.6) yearsNFI + AMI: N = 65 (58 analysed)60.0% male; mean age = 26.1 (SD 6.1) years                                                                                                                                                                                                             70.9%All: 38.7%NFI: 49.2%NFI + AMI: 29.2%                                                                                                                   20.5% (9 of 44) of participants in the NFI group remitted from psychotic experiencesSig. within-group improvement for NFI for basic & positive psychosis spectrum symptoms (ERI-BAPPSS p\<0.01), positive psychosis spectrum (ERI-PPS, p\<0.05), basic symptoms (ERI-BS, p\<0.01), general psychopathology (PANSS-G, p\<0.05), and depression symptoms (MADRS, p\<0.05).

  [@bibr65-0004867420913118]^56^China           Positive and negative psychotic symptoms, depression, functioning, self-esteem, social support                                                                                     Systemic Therapy Supportive Therapy (ST)                                                                                                                                         Single-blind RCTPost-intervention only (6 mo. post-baseline)                                                                                                    N = 26Systemic: N = 1335.8% male; mean age = 18.9 (SD 1.0) yearsST: N = 1361.5% male; mean age = 18.9 (SD 1.3) years                                                                                                                                                                                                                                                           81.3%0%                                                                                                                                                     No sig. between-group differences on any outcome measure: 61.5% of participants in systemic therapy group remitted from attenuated psychotic symptoms as compared with 46.2% of participants in supportive therapy group. Sig. within-group improvements for systemic therapy group in positive symptoms (d=0.53, p=0.005), depressive symptoms (d=0.75, p=0.010), self-esteem (d=0.59, p=0.011), and social support (d=0.45, p=0.013). No sig. within-group improvements for supportive therapy group.

  [@bibr67-0004867420913118]^57^Australia       Psychotic-like experiences, distress                                                                                                                                               CBT (online intervention)\                                                                                                                                                       Pre-postPost-intervention only (3 mo. post-baseline)                                                                                                            N = 1225.0% male; mean age = 22.6 (SD 4.0) years                                                                                                                                                                                                                                                                                                                               71%0%                                                                                                                                                       Sig. reduction in number (d=0.64, p\<0.005) and frequency of psychotic-like experiences (d=0.89, p\<0.005) and associated distress (d=0.53, p\<0.005). No sig. pre-post difference in K10 score, but 25% reduction in number of participants who scored 17 or above on the K10 (100% to 75%).
                                                                                                                                                                                                                                   NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  [@bibr69-0004867420913118]^58^Australia       Primary: transition to psychosisSecondary: severity of psychotic symptoms, distress associated with psychotic symptoms, depression, anxiety, social functioning, quality of life   CBTNon-Directive Reflective Listening (NDRL)                                                                                                                                     Single-blind RCTPost-intervention, 6 mo. post-intervention (6 & 12 mo. post-baseline)                                                                           N = 57CBT: N = 3033.3% male; mean age = 16.2 (SD 2.7) yearsNDRL: N = 2748.1% male; mean age = 16.5 (SD 3.2) years                                                                                                                                                                                                                                                              58.2%CBT: 60%NDLR: 44.4%                                                                                                                                    Sig. improvement in distress associated with subclinical psychotic symptoms in favour of NDRL (p=0.029). No other between-group differences in any measures (i.e. frequency/intensity of psychotic experiences, anxiety, depression, overall symptom severity, global/social/role functioning).

  [@bibr71-0004867420913118]^59^Netherlands     Primary: transition to psychosisSecondary: depression, anxiety, quality of life, social functioning, personal beliefs about illness                                                CBT + TAUTAU                                                                                                                                                                     RCTPost-intervention, 6 & 12 mo. post-intervention (6, 12 & 18 mo. post-baseline)                                                                               N = 201CBTuhr + TAU: N = 9850.0% male; mean age = 22.9 (SD 5.6) yearsTAU: N = 10348.5% male; mean age = 22.6 (SD 5.5) years                                                                                                                                                                                                                                                    77.9%CBTuhr + TAU: 14.4%TAU: 12.5%                                                                                                                          Across both groups, 35% of participants were in remission from ARMS at 6 mo. post-baseline, 48% at 12 mo. post-baseline, and 63% at 18 mo. post-baseline. The proportion of participants who remitted was higher in the CBTuhr group than in the TAU group (70.4% vs. 57.0% at end of study; p=0.039). No sig. between-group differences at 6, 12, or 18 mo. post-baseline amongst non-transitioning participants in frequency/intensity of subclinical psychotic symptoms, depression, anxiety, quality of life, or social functioning. Distress from subclinical psychotic symptoms was significantly lower in the CBTuhr group than in the TAU group at 6 mo. post-baseline (p=0.012). Across both groups, percentage of participants with clinical depression decreased from \~60% to \<20% and clinical social phobia from \~40% to \<20% from baseline to 18 mo. post-baseline.
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: ND (not described), NA (not applicable), RCT (randomised controlled trial); **Treatments:** CBCM (cognitive behavioural therapy with case management), CBT (cognitive behavioural therapy), CT (cognitive therapy), IPI (integrated psychological therapy), MBCT (mindfulness-based cognitive therapy), NBI (needs-based intervention), NFI (needs-focused intervention), NDRL (non-directive reflective listening), PUFAs (poly-unsaturated fatty acids), SPI (specific preventive intervention), ST (supportive therapy), SC (supportive counselling), TAU (treatment as usual). **Measures:** BPRS (Brief Psychiatric Rating Scale), CAARMS (Comprehensive Assessment of At-Risk Mental States), ERI BAPPSS/PPS/BS (Early Recognition Inventory Basic and Positive Psychotic Spectrum Symptoms/Psychotic Positive Symptoms/Basic Symptoms), K10 (10-item Kessler Psychological Distress Scale), MADRS (Montgomery-Åsberg Depression Rating Scale), PANSS (Positive and Negative Syndrome Scale), QLS (Quality of Life Scale), SAS (Social Anxiety Scale), SIAS (Social Interaction Anxiety Scales). **Notes:** ^1^If study authors have explicitly listed outcomes, these are reflected; if not, outcomes are inferred based on results and discussion. ^2^Psychopharmacological and dietary treatments (which meet our exclusion criteria) included for completeness only when they are compared with a psychological intervention. ^3^No explicit follow-up times are presented in the original paper; these were chosen by the reviewers (with full access to study data) to maximise comparison in meta-analysis

![PRISMA flowchart ([@bibr38-0004867420913118]).](10.1177_0004867420913118-fig1){#fig1-0004867420913118}

### CBT {#section19-0004867420913118}

CBT for PEs (and other therapies where CBT is the key component, e.g. integrated psychological interventions) ([@bibr2-0004867420913118]; [@bibr6-0004867420913118], [@bibr7-0004867420913118]; [@bibr20-0004867420913118]; [@bibr32-0004867420913118], [@bibr30-0004867420913118], [@bibr31-0004867420913118]; [@bibr35-0004867420913118]; [@bibr41-0004867420913118], [@bibr40-0004867420913118]; [@bibr44-0004867420913118]; [@bibr49-0004867420913118], [@bibr48-0004867420913118]; [@bibr52-0004867420913118]; [@bibr67-0004867420913118]; [@bibr69-0004867420913118]; [@bibr71-0004867420913118]) explores the links between thoughts, emotions and behaviour. The therapy is formulation-driven, problem-oriented, time-limited, and tailored to patients' needs. The key components include patient engagement, creation of a mutually-agreed problem list, formulation, normalisation of PEs and patients' interpretations of them, evaluation of alternative explanations, and behavioural experiments to challenge patients' appraisals of PEs.

### Cognitive remediation {#section20-0004867420913118}

Cognitive remediation refers to behavioural training aimed at improving cognitive processes (e.g. attention, memory and executive function) ([@bibr5-0004867420913118]). The cognitive remediation intervention included in this review focuses on improving auditory processing in people with PEs ([@bibr60-0004867420913118]). It is computer-based and includes several different exercises to improve the diverse aspects of auditory processing.

### Family-focused therapy {#section21-0004867420913118}

This therapy ([@bibr54-0004867420913118]) treats people with PEs in the context of the family. The key components include psychoeducation around topics such as symptoms, daily stressors, coping strategies, the vulnerability--stress perspective, family support, and prevention action plans. Family members learn a structured approach to defining problems, breaking down complex problems, brainstorming solutions, analysing pros and cons of possible solutions, and selecting and implementing action plans.

### Family psychoeducational intervention {#section22-0004867420913118}

The included family psychoeducational intervention ([@bibr54-0004867420913118]) was a brief, three-session process of providing education and information. The content mirrored that of the psychoeducation aspect of the FFT described above.

### Mindfulness-based cognitive therapy {#section23-0004867420913118}

Mindfulness-based cognitive therapy (MBCT; [@bibr36-0004867420913118]) includes psychoeducation and exercises to demonstrate the links between thinking and feeling. Specific techniques include 'Body Scan' training, mindful breathing, breathing space, yoga, and sitting meditation. The intervention uses a group-based format.

### Sleep CBT {#section24-0004867420913118}

The sleep CBT included this review ([@bibr8-0004867420913118]) used the 'SleepWell' treatment package, which utilises CBT techniques to address insomnia and circadian rhythm disruption to reduce sleep disturbances. Therapists use individualised formulation of sleep problems to identify treatment targets and actigraphy data to monitor changes in sleep patterns and highlight potential areas for change.

### Strengths and mindfulness-based online social therapy {#section25-0004867420913118}

This intervention, set within a social media context, takes a strengths and mindfulness-based focus, and uses a self-determination theory of motivation to foster self-efficacy and increase positive emotions ([@bibr3-0004867420913118]). The intervention provides social 'online' support moderated by expert and peer moderators. Modules addressed personal strengths, mindfulness, connecting with others, and group problem-solving to promote self-efficacy and interpersonal problem-solving.

### Systemic therapy {#section26-0004867420913118}

Systemic therapy ([@bibr65-0004867420913118]) is centred around systemic-constructivist and psychosocial resilience theories. The therapy focuses on solutions and resources, and encourages patients to reframe their problems and better understand their available resources in order to solve these problems.

### Supportive treatments {#section27-0004867420913118}

As stated above, the category of STs includes supportive therapy, supportive counselling, non-directive reflective listening, NBI, and needs-focused intervention ([@bibr2-0004867420913118]; [@bibr7-0004867420913118]; [@bibr35-0004867420913118]; [@bibr41-0004867420913118]; [@bibr59-0004867420913118]; [@bibr63-0004867420913118]; [@bibr65-0004867420913118]; [@bibr69-0004867420913118]). In general, these interventions use general counselling techniques, including warm, empathic, and non-judgmental face-to-face contact and supportive listening. They do not include active therapeutic techniques.

The quality of included studies was mixed ([Table 2](#table2-0004867420913118){ref-type="table"}); 21 of the 27 reports used an RCT design, of which only 4 received a global rating of 'strong', 10 received a global rating of 'moderate', and 7 received a global rating of 'weak'. Selection bias, confounding, and drop-out were the categories that most limited the global ratings (it should be noted that a rating of 'strong' in the selection bias category is not achievable when only help-seeking patients are included. Importantly, no study was excluded in the sensitivity analyses based solely on studying a help-seeking population). The remaining four studies used a pre--post design -- relatively, a much weaker study design -- but none of these received a 'weak' rating in any of the applicable categories.

###### 

Quality of included studies (EPHPP rating tool).

![](10.1177_0004867420913118-table2)

  First author (year); study design                        Selection bias   Study design   Confounders   Blinding   Data collection   Drop-out   Global rating^[a](#table-fn6-0004867420913118){ref-type="table-fn"}^
  -------------------------------------------------------- ---------------- -------------- ------------- ---------- ----------------- ---------- ----------------------------------------------------------------------
  [@bibr2-0004867420913118], RCT                           Weak             Strong         Strong        Moderate   Strong            Weak       Weak
  [@bibr3-0004867420913118], pre--post                     Moderate         Moderate       *NA*          *NA*       Strong            Strong     *NA*
  [@bibr7-0004867420913118], RCT                           Moderate         Strong         Strong        Moderate   Strong            Weak       Moderate
  [@bibr6-0004867420913118], pre--post                     Moderate         Moderate       *NA*          *NA*       Strong            Strong     *NA*
  [@bibr8-0004867420913118], A-B                           Moderate         Moderate       *NA*          *NA*       Strong            Strong     *NA*
  [@bibr20-0004867420913118], pre--post                    Moderate         Moderate       *NA*          *NA*       Strong            Moderate   *NA*
  [@bibr31-0004867420913118], economic evaluation of RCT   Weak             Strong         Strong        Moderate   Strong            Weak       Weak
  [@bibr30-0004867420913118], RCT                          Moderate         Strong         Strong        Moderate   Strong            Weak       Moderate
  [@bibr32-0004867420913118], economic evaluation of RCT   Weak             Strong         Strong        Moderate   Strong            Strong     Moderate
  [@bibr35-0004867420913118], RCT                          Moderate         Strong         Strong        Moderate   Strong            Moderate   Strong
  [@bibr36-0004867420913118], quasi-RCT                    Weak             Strong         Weak          Moderate   Strong            Weak       Weak
  [@bibr44-0004867420913118], pre--post                    Moderate         Moderate       NA            NA         Strong            Strong     *NA*
  [@bibr40-0004867420913118], RCT                          Moderate         Strong         Weak          Strong     Strong            Moderate   Moderate
  [@bibr41-0004867420913118], RCT                          Weak             Strong         Strong        Strong     Strong            Moderate   Moderate
  [@bibr42-0004867420913118], RCT                          Weak             Strong         Strong        Weak       Strong            Strong     Weak
  [@bibr48-0004867420913118], RCT                          Moderate         Strong         Strong        Moderate   Strong            Weak       Moderate
  [@bibr49-0004867420913118], RCT                          Moderate         Strong         Strong        Moderate   Strong            Moderate   Strong
  [@bibr51-0004867420913118], RCT                          Moderate         Strong         Weak          Strong     Strong            Strong     Moderate
  [@bibr54-0004867420913118], RCT                          Moderate         Strong         Strong        Moderate   Strong            Weak       Moderate
  [@bibr58-0004867420913118], economic evaluation of RCT   Weak             Strong         Strong        Strong     Strong            Moderate   Moderate
  [@bibr59-0004867420913118], RCT                          Moderate         Strong         Strong        Weak       Strong            Moderate   Moderate
  [@bibr60-0004867420913118], RCT                          Moderate         Strong         Weak          Moderate   Strong            Weak       Weak
  [@bibr63-0004867420913118], RCT                          Moderate         Strong         Strong        Weak       Strong            Weak       Weak
  [@bibr65-0004867420913118], RCT                          Moderate         Strong         Strong        Moderate   Strong            Strong     Strong
  [@bibr67-0004867420913118], pre--post                    Moderate         Moderate       *NA*          *NA*       Strong            Strong     *NA*
  [@bibr69-0004867420913118], RCT                          Moderate         Strong         Weak          Moderate   Strong            Weak       Weak
  [@bibr71-0004867420913118], RCT                          Moderate         Strong         Strong        Moderate   Strong            Strong     Strong

EPHPP: Effective Public Health Practice Project; RCT: randomised controlled trial; NA: not applicable.

Global ratings are not provided for studies with *NA* ratings in any category to ensure comparability of results (personal communication with EPHPP team, 19 September 2017).

Primary outcome {#section28-0004867420913118}
---------------

Five reports from four studies provided the proportion of participants that remitted from PEs following psychological intervention ([@bibr30-0004867420913118]; [@bibr44-0004867420913118]; [@bibr63-0004867420913118]; [@bibr65-0004867420913118]; [@bibr71-0004867420913118]). Meta-analysis was not possible for the primary outcome: only two reports had the same intervention framework and comparator category, and the more recent was a follow-up of the first ([@bibr30-0004867420913118]; [@bibr71-0004867420913118]).

### CBT {#section29-0004867420913118}

Both studies of CBT used the Comprehensive Assessment of At-Risk Mental States (CAARMS; [@bibr77-0004867420913118]) to determine remission status. In an RCT examining differences between CBT + TAU versus TAU, 70.4% of participants receiving CBT + TAU had remitted from at-risk mental state (ARMS) status by 12 months post-intervention, as compared with 57.0% of participants receiving TAU only (*p* = 0.039) ([@bibr71-0004867420913118]). The difference remained significant at medium-term follow-up (approximately 3.5 years post-therapy), with 76.3% of the CBT + TAU group versus 58.7% of the TAU only group in remission (*p* = 0.04) ([@bibr30-0004867420913118]). A pre--post study of CBT found ARMS remission rates of 46.2% at post-intervention and 84.6% 6 months post-intervention ([@bibr44-0004867420913118]).

### Other frameworks {#section30-0004867420913118}

An RCT comparing systemic therapy with supportive therapy found greater remission from clinical high-risk status (measured using the Scale of Prodromal Symptoms; [@bibr46-0004867420913118]) among those receiving systemic therapy (61.5% versus 46.2%), but the difference was not significant (*p* = 0.431) ([@bibr65-0004867420913118]). Finally, a trial of a needs-focused intervention found a 20.5% remission rate from all psychotic symptoms (assessed with the Early Recognition Inventory -- Positive Psychosis Spectrum \[ERI-PPS\]; [@bibr34-0004867420913118]) at post-therapy ([@bibr63-0004867420913118]).

Secondary outcomes {#section31-0004867420913118}
------------------

As mentioned above, we were only able to include studies of CBT in our meta-analyses, as CBT was the only framework examined in two or more studies.

### CBT {#section32-0004867420913118}

We included eight reports from seven studies in our meta-analyses ([Figures 2](#fig2-0004867420913118){ref-type="fig"}[](#fig3-0004867420913118){ref-type="fig"}[](#fig4-0004867420913118){ref-type="fig"}[](#fig5-0004867420913118){ref-type="fig"}[](#fig6-0004867420913118){ref-type="fig"}[](#fig7-0004867420913118){ref-type="fig"}--[8](#fig8-0004867420913118){ref-type="fig"}), four of which compared CBT (with or without TAU) with TAU only. CBT was superior to TAU in reducing distress (pooled SMD = −0.24 favouring CBT; 95% CI = \[−0.37, −0.10\]). No other statistically significant differences were found for positive psychotic symptoms (pooled SMD = −0.14 favouring CBT; 95% CI = \[−0.32, 0.04\]), depression (pooled SMD = −0.15 favouring CBT; 95% CI = \[−0.35, 0.06\]), anxiety (pooled SMD = −0.02 favouring CBT; 95% CI = \[−0.22, 0.18\]), functioning (pooled SMD = −0.09 favouring TAU; 95% CI = \[−0.22, 0.04\]), or quality of life (pooled SMD = −0.03 favouring TAU; 95% CI = \[−0.24, 0.18\]).

![Positive psychotic symptoms: meta-analysis summary plot (NB: follow-up times are measured from the end of the intervention).\
CBT: cognitive behavioural therapy; TAU: treatment as usual; ST: supportive treatments.](10.1177_0004867420913118-fig2){#fig2-0004867420913118}

![Negative psychotic symptoms: meta-analysis summary plot (NB: follow-up times are measured from the end of the intervention).\
CBT: cognitive behavioural therapy; TAU: treatment as usual; ST: supportive treatments.](10.1177_0004867420913118-fig3){#fig3-0004867420913118}

![Distress: meta-analysis summary plot (NB: follow-up times are measured from the end of the intervention).\
CBT: cognitive behavioural therapy; TAU: treatment as usual; ST: supportive treatments.](10.1177_0004867420913118-fig4){#fig4-0004867420913118}

![Depression: meta-analysis summary plot (NB: follow-up times are measured from the end of the intervention).\
CBT: cognitive behavioural therapy; TAU: treatment as usual; ST: supportive treatments.](10.1177_0004867420913118-fig5){#fig5-0004867420913118}

![Anxiety: meta-analysis summary plot (NB: follow-up times are measured from the end of the intervention).\
CBT: cognitive behavioural therapy; TAU: treatment as usual; ST: supportive treatments.](10.1177_0004867420913118-fig6){#fig6-0004867420913118}

![Functioning: meta-analysis summary plot (NB: follow-up times are measured from the end of the intervention).\
CBT: cognitive behavioural therapy; TAU: treatment as usual; ST: supportive treatments.](10.1177_0004867420913118-fig7){#fig7-0004867420913118}

![Quality of life: meta-analysis summary plot (NB: follow-up times are measured from the end of the intervention).\
CBT: cognitive behavioural therapy; TAU: treatment as usual; ST: supportive treatments.](10.1177_0004867420913118-fig8){#fig8-0004867420913118}

Four additional reports compared CBT with an ST (e.g. supportive therapy, supportive counselling or non-directive reflective listening). No statistically significant differences were found for positive psychotic symptoms (pooled SMD = −0.12 favouring CBT; 95% CI = \[−0.61, 0.38\]), negative psychotic symptoms (pooled SMD = 0.14 favouring ST; 95% CI = \[−0.30, 0.57\]), depression (pooled SMD = 0.09 favouring ST; 95% CI = \[−0.33, 0.52\]), anxiety (pooled SMD = −0.18 favouring CBT; 95% CI = \[−0.71, 0.34\]), or functioning (pooled SMD = −0.15 favouring CBT; 95% CI = \[−0.29, 0.59\]).

To determine whether there was a difference between the two different control groups, we included TAU and ST as predictors of SMD in a meta-regression model. Because there was not a statistically significant difference between the different control groups for any outcome, we also computed a pooled estimate for all reports regardless of comparator. When TAU and ST were collapsed into a single comparator group, CBT remained more effective than the combined TAU/ST comparison groups at reducing distress (pooled SMD: −0.23 favouring CBT; 95% CI = \[−0.36, −0.10\]). There were no other statistically significant differences between CBT and controls.

Most of these meta-analyses suffered from high heterogeneity (Cochran's *Q, p* \< 0.05). However, this measure is unreliable when the number of studies included is very low, so although heterogeneity cannot be ruled out, it is hard to ascertain its extent.

Two reports found significant between-group differences in severity of psychotic symptoms in two distinct trials, in each instance favouring cognitive therapy (*p* = 0.049 and *p* = 0.018, respectively) ([@bibr49-0004867420913118], [@bibr48-0004867420913118]). A further two reports found significant between-group differences in distress, but in opposite directions: while one found lower distress among participants in the CBT group (*p* = 0.012) ([@bibr71-0004867420913118]), the other found lower distress among participants in the non-directive reflective listening (ST) group (*p* = 0.029) ([@bibr69-0004867420913118]). No RCT found any statistically significant between-group differences for depression, anxiety, functioning, or quality of life.

In addition, reports from three controlled ([@bibr2-0004867420913118]; [@bibr7-0004867420913118]; [@bibr40-0004867420913118]) and four uncontrolled studies ([@bibr6-0004867420913118]; [@bibr20-0004867420913118]; [@bibr44-0004867420913118]; [@bibr67-0004867420913118]) provided results of significance tests for within-group pre--post changes for individuals receiving CBT (several more noted symptom improvement, but did not provide formal significance testing results). The three reports providing data on positive psychotic symptoms ([@bibr2-0004867420913118]; [@bibr44-0004867420913118]; [@bibr67-0004867420913118]), and one of the three providing data on negative psychotic symptoms ([@bibr40-0004867420913118]) found significant improvement. Significant improvement was also noted in four of the five reports providing data on depression ([@bibr6-0004867420913118]; [@bibr20-0004867420913118]; [@bibr40-0004867420913118]; [@bibr44-0004867420913118]) and functioning ([@bibr6-0004867420913118], [@bibr7-0004867420913118]; [@bibr40-0004867420913118]; [@bibr44-0004867420913118]), all four reports providing data on anxiety ([@bibr2-0004867420913118]; [@bibr6-0004867420913118]; [@bibr20-0004867420913118]; [@bibr44-0004867420913118]), one of the two providing data on distress ([@bibr20-0004867420913118]), and in the one report that provided data on quality of life ([@bibr44-0004867420913118]). No study found statistically significant decline in any domain.

### Supportive treatments {#section33-0004867420913118}

Reports from five controlled studies ([@bibr2-0004867420913118]; [@bibr7-0004867420913118]; [@bibr59-0004867420913118]; [@bibr63-0004867420913118]; [@bibr65-0004867420913118]) provided results from significance testing for within-group pre--post changes for individuals receiving supportive or needs-focused treatments. Two of four reports providing data on positive psychotic symptoms ([@bibr2-0004867420913118]; [@bibr63-0004867420913118]), but none of the four providing data on negative psychotic symptoms, found significant improvement. Significant improvement was noted in two of four reports providing data on depression ([@bibr2-0004867420913118]; [@bibr63-0004867420913118]), one of two providing data on anxiety ([@bibr2-0004867420913118]), one of five providing data on functioning ([@bibr7-0004867420913118]), and in the one report providing data on in quality of life ([@bibr59-0004867420913118]). No study found statistically significant decline in any domain.

### Other intervention frameworks {#section34-0004867420913118}

Four additional RCTs focused on systemic therapy ([@bibr65-0004867420913118]), MBCT ([@bibr36-0004867420913118]), FFT ([@bibr54-0004867420913118]), and cognitive remediation therapy (CRT) ([@bibr60-0004867420913118]). Only the MBCT trial showed any between-group differences in our outcomes of interest. In this study, MBCT was more effective than the control condition (a video viewing forum) at reducing anxiety from baseline to post-therapy (*d* = 0.88, *p* = 0.012) as well as baseline to 12-week follow-up (*d* = 0.91, *p* = 0.048). However, they found no other significant between-group differences for psychotic symptoms or distress ([@bibr36-0004867420913118]).

Systemic therapy, CRT and FFT were no more effective than their control treatments (supportive therapy, computer games, and family psychoeducation, respectively) ([@bibr54-0004867420913118]; [@bibr60-0004867420913118]; [@bibr65-0004867420913118]). Although neither systemic therapy nor CRT was more effective than its control treatment, each showed within-group pre--post effects. Individuals who received systemic therapy showed significant reductions in positive symptoms (*d* = 0.53, *p* = 0.005) and depressive symptoms (*d* = 0.75, *p* = 0.010) from baseline to post-therapy, while no such changes were found for the supportive therapy group ([@bibr65-0004867420913118]). Similarly, individuals assigned to CRT had significant improvements in social functioning (*p* \< 0.05) from baseline to 6 months post-intervention, while those assigned to the computer games condition had no significant improvements ([@bibr60-0004867420913118]).

A further two uncontrolled studies examined within-group pre--post effects of a strengths and mindfulness-based online social therapy ([@bibr3-0004867420913118]) and a CBT intervention for sleep problems ([@bibr8-0004867420913118]). The former found significant improvements in social functioning (*d* = 1.83, *p* \< 0.001) from baseline to post-intervention ([@bibr3-0004867420913118]), and the latter found significant improvements in depression and quality of life (*p* \< 0.05; exact values not given). These improvements were maintained at 1 month post-therapy, at which time improvement in paranoia and hallucinations also reached significance (*p* \< 0.05; exact values not given) ([@bibr8-0004867420913118]).

Sub-group analyses {#section35-0004867420913118}
------------------

For sub-group analyses by quality, we were only able to perform two meta-analyses (for functioning and positive symptoms) due to the fact that in all other meta-analyses there was only one study without a high risk of bias in at least one category. We found no statistically significant difference between CBT and TAU in either sub-group analysis (see [Supplemental Appendix E](https://journals.sagepub.com/doi/suppl/10.1177/0004867420913118)).

Components of effective interventions {#section36-0004867420913118}
-------------------------------------

We focused our components analysis on the five interventions that showed effectiveness for at least one outcome *in controlled trials*: three CBT ([@bibr49-0004867420913118], [@bibr48-0004867420913118]; [@bibr71-0004867420913118]), one mindfulness-based cognitive therapy ([@bibr36-0004867420913118]), and one non-directive reflective listening intervention ([@bibr69-0004867420913118]) (intervention components in [Supplemental Appendix D](https://journals.sagepub.com/doi/suppl/10.1177/0004867420913118)). Qualitative examination of the components of these five therapies revealed high heterogeneity: very few components were shared across the effective therapies, which is unsurprising given their differing frameworks. Furthermore, there were no 'key ingredients' that were particular to these five therapies: although there were some common components across the effective therapies (e.g. mode of delivery), these were also shared by therapies that did not demonstrate effectiveness.

Economic studies {#section37-0004867420913118}
----------------

Four reports met inclusion criteria for the economic component of the review (summary of studies' characteristics in [Supplemental Appendix F](https://journals.sagepub.com/doi/suppl/10.1177/0004867420913118); quality assessment in [Supplemental Appendix G](https://journals.sagepub.com/doi/suppl/10.1177/0004867420913118); full economic analysis in [Supplemental Appendix H](https://journals.sagepub.com/doi/suppl/10.1177/0004867420913118)). Two focused on CBT ([@bibr32-0004867420913118], [@bibr31-0004867420913118]) and two on ST ([@bibr59-0004867420913118], [@bibr58-0004867420913118]).

### CBT {#section38-0004867420913118}

[@bibr32-0004867420913118], [@bibr31-0004867420913118]) reported the results of full economic evaluations in two reports, which were based on 18-month and 4-year post-baseline data, respectively, from a study conducted in the Netherlands between 2008 and 2010 comparing routine care plus CBT for the prevention of psychosis with routine care alone for individuals at ultra-high risk aged 14 to 35 years ([@bibr62-0004867420913118]). At 18 months post-baseline, the authors concluded that CBT proved to be cost-saving; however, differences in costs between groups were not tested statistically. When combined with outcome data, there was some evidence to suggest that CBT plus routine care may be cost-effective compared to routine care alone, but differences were small and no assessment of uncertainty was carried out. Results were clearer at 4 years post-baseline, with evidence to suggest a high probability (\>80%) of the CBT group being cost-effective compared with routine care alone.

### Supportive treatments {#section39-0004867420913118}

[@bibr59-0004867420913118], [@bibr58-0004867420913118]) explored resource use and cost-savings in two reports, both based on data from an RCT conducted in Australia between 1996 and 1999, which compared a NBI with NBI plus a specific preventive intervention (SPI) including psychotherapy and neuroleptic medication for individuals aged 14 to 30 years at ultra-high risk ([@bibr42-0004867420913118]). [@bibr59-0004867420913118] explored resource use from a mental health service perspective between 12 and 36 months post-randomisation. Resource use was reported by group for some resource items and by those who did or did not develop psychosis for others. There was little difference in resource use with the exception of significantly higher mental health service use for those who did not develop psychosis in the control arm. However, sample sizes were small (total *n* = 41) and cost differences were not tested statistically. In [@bibr58-0004867420913118], a cost-savings analysis was undertaken for the full 36-month post-baseline follow-up period. There were no significant differences in total cost between the groups over the full follow-up. In terms of outcomes ([@bibr59-0004867420913118]), no differences in the rate of transition to psychotic disorder, level of symptomatology, or functioning between the groups were identified, therefore indicating there may be no cost-effectiveness advantage of the intervention.

Discussion {#section40-0004867420913118}
==========

This systematic review and meta-analysis included 27 reports concerning 21 studies of psychological interventions for PEs and aimed to determine their effectiveness and cost-effectiveness for improving a range of clinical and functional outcomes. In terms of the proportion of participants remitting from PEs, we found preliminary evidence from one RCT and one uncontrolled study for the potential effectiveness of CBT. We did not find meta-analytic evidence that CBT improved PEs on a continuous scale, though it is likely that our analyses were underpowered to detect small effects. While two individual RCTs favoured CBT over TAU for reducing the severity of psychotic symptoms, this effect was not consistent across all controlled studies. CBT, sleep CBT, and systemic therapy -- but not ST -- also showed promise in terms of within-group pre--post improvements in psychotic symptoms.

For our other non-psychotic secondary outcomes (depression, anxiety, functioning, distress and quality of life), only the meta-analysis of distress outcomes revealed evidence of comparative effectiveness, by which CBT was more effective than comparators. However, a high degree of heterogeneity cannot be ruled out in this meta-analysis, meaning that CBT may not reduce distress in all implementation scenarios in this patient population. Two individual trials showed a significant effect on distress, but in opposite directions. The only other RCT evidence of effectiveness was for mindfulness CBT, which significantly reduced participants' anxiety symptoms. Low-quality evidence from uncontrolled studies showed that a number of therapies were effective for at least one non-psychotic clinical or functional outcome, including CBT, sleep CBT, systemic therapy, CRT, and mindfulness online social therapy. Supportive treatments were fairly effective at improving anxiety and depression, but not other outcomes.

The overall quality of studies included in the effectiveness component of the review was variable. While most reports (21 of the 27) focused on data from RCTs (the gold standard study design for investigating intervention effect), all but four of these received a rating indicating high risk of bias in at least one of the rating categories. High rates of attrition were the predominant reason for lower ratings, followed by high chance of selection bias. The six non-randomised, uncontrolled studies, although prone to the significant biases associated with low-quality study design, did not receive any rating indicating high risk of bias in any other applicable category (these were not rated in terms of blinding or confounders).

Economic data meeting the inclusion criteria were only available in four publications, which used data from two RCTs, one focusing on CBT and the other focusing on an intervention that included psychotherapy and antipsychotic medication. Both interventions were targeted at young adults at ultra-high risk of psychosis. The included economic studies were methodologically strong, meeting most of the Drummond checklist quality assessment criteria ([@bibr17-0004867420913118]). The economic studies focusing on CBT indicate that the addition of CBT to routine care has a high probability of being cost-effective compared to routine care alone in this ultra-high risk group.

Several previous systematic reviews and meta-analyses have examined the effectiveness of psychological, pharmacological, and nutritional interventions for people with PEs. Although most reviews focused primarily on transition (and four focused exclusively on transition), seven ([@bibr14-0004867420913118]; [@bibr16-0004867420913118]; [@bibr28-0004867420913118]; [@bibr43-0004867420913118]; [@bibr55-0004867420913118]; [@bibr68-0004867420913118]; [@bibr72-0004867420913118]) also reported selected secondary outcomes that do correspond with the current review's focus, specifically psychotic symptoms ([@bibr14-0004867420913118]; [@bibr16-0004867420913118]; [@bibr43-0004867420913118]; [@bibr55-0004867420913118]; [@bibr68-0004867420913118]), distress ([@bibr28-0004867420913118]; [@bibr55-0004867420913118]), depression ([@bibr43-0004867420913118]; [@bibr55-0004867420913118]; [@bibr68-0004867420913118]), anxiety ([@bibr43-0004867420913118]; [@bibr55-0004867420913118]), functioning ([@bibr28-0004867420913118]; [@bibr43-0004867420913118]; [@bibr55-0004867420913118]; [@bibr72-0004867420913118]), and quality of life ([@bibr28-0004867420913118]; [@bibr43-0004867420913118]; [@bibr55-0004867420913118]; [@bibr68-0004867420913118]). Importantly, no prior review has included a consideration of remission from PEs. None of these reviews (including the review upon which current UK clinical guidelines are based) has found strong evidence to support the effectiveness of any particular psychological intervention for improving our outcomes of interest within this population. In general, these reviews reflect our own results. However, departing from previous findings, we found meta-analytic evidence that distress was significantly reduced after CBT as compared with control treatments (TAU/ST). It is possible that distress is a significant, under-measured, and under-reported outcome in the literature; indeed, only two previous reviews have reported distress as an outcome. Distress is an important factor to individuals with PEs as reductions can be interpreted as improvement, despite residual symptoms ([@bibr10-0004867420913118]; [@bibr23-0004867420913118]; [@bibr37-0004867420913118]); consequently, a broader consideration of this outcome is warranted.

Major treatment guidelines currently recommend CBT for the treatment of people at-risk for developing psychosis ([@bibr1-0004867420913118]; [@bibr19-0004867420913118]; [@bibr50-0004867420913118]; [@bibr64-0004867420913118]). In the United Kingdom, [@bibr50-0004867420913118] highlights the value of CBT for preventing transition to frank psychotic disorder. However, recent meta-analytic evidence published since the creation of these guidelines suggests that CBT for populations at-risk for developing psychosis may not be superior to other inventions in preventing transition ([@bibr13-0004867420913118]), although it is important to note that concerns have been raised about both the methodology and interpretation of results in this review ([@bibr51-0004867420913118]). Our findings provide initial evidence that, while doubts remain about its effectiveness in terms of preventing transition to psychosis, CBT may nevertheless be more effective than other approaches at promoting *remission* from PEs and reduction of associated distress, and thus may still be considered as a potentially useful intervention for treating people with PEs. Conversely, when the aim of psychological intervention is to reduce other clinical symptoms (e.g. depression and anxiety) or functional impairment associated with PEs, CBT falls short in demonstrating effectiveness as compared with other treatments. This is an important shortcoming, as poor clinical and functional outcomes may serve to perpetuate mental ill health that may still require more than just monitoring for changes in post-CBT persistent symptoms, as currently recommended by [@bibr50-0004867420913118].

Strengths and limitations {#section41-0004867420913118}
-------------------------

This review has a number of important strengths and addresses key gaps in the literature concerning psychological interventions for people with PEs. First, to our knowledge, we were the first to meta-analyse studies across such a broad range of clinical and functional outcomes. Second, we focus on remission from PEs, a new and important outcome that was developed in collaboration with our lived experience advisory panel. Third, we include economic outcomes, which again have not been reviewed previously. Fourth, we review a large number of studies not included in any other review, including, importantly, studies of newer, non-CBT frameworks.

These strengths notwithstanding, our review, and in particular our meta-analyses, has a number of limitations. First, each meta-analysis included a small number of reports, each of which had a limited number of participants (sometimes short of the recruitment target). This will have reduced our power to detect small, but potentially clinically meaningful, treatment effects. We aimed to increase power by including multiple study follow-up points within each meta-analysis. Although we could also have combined outcomes to reduce the total number of meta-analyses (and also the probability of type I error), we chose not to do this as (1) sometimes outcomes changed in different directions following intervention (e.g. see [@bibr36-0004867420913118]), and (2) Cochrane warns against combining heterogeneous outcomes (see section 9.1.4) ([@bibr26-0004867420913118]). Second, the high number of meta-analyses performed will have increased the probability of false positive results, which is particularly important in our analyses due to the fact that we found only one significant effect. Third, we could not rule out high heterogeneity within our meta-analyses. Fourth, our decision to group several therapy types under 'supportive therapy' was not without limitations; for example, patients under TAU conditions may well receive CBT for other mental health problems outside of PEs (e.g. depression or anxiety). Fifth, our exclusion criteria regarding age range and antipsychotic use may limit the generalisability of our findings to younger populations or patients prescribed antipsychotic medication as part of their treatment plan. Sixth, in terms of the studies themselves, while many utilised randomised controlled designs, the overall methodological quality was not high; only four studies received a global rating of 'high' on the quality rating tool. Finally, we acknowledge that we were not able to fulfil all a priori review aims. While the review was ambitious, we contend that it was not possible to predict which aims could and could not be accomplished. Furthermore, we believe that highlighting gaps in the literature is an important step in moving the field forward.

Conclusion {#section42-0004867420913118}
==========

This review has clear clinical relevance and will be central in the development of a new therapeutic framework for IAPT, as well as for other programmes aiming to address PEs in primary mental healthcare settings internationally. The broad aims, comprehensive outcomes, and specific selection criteria all reflect this purpose. The review will ensure any decisions concerning treatment development and treatment selection for people with PEs within primary care are supported by the most recent and high-quality evidence. Overall, our findings indicate that clinicians must consider a wider range of clinical and functional outcomes as well as interventions for people with PEs that go beyond strategies for preventing transition to psychotic disorders. Our systematic review and meta-analysis suggest that, despite its limited effectiveness in preventing transitions, CBT may be useful to reduce the distress associated with PEs and cost-effective in comparison with treatment as usual. However, the scarcity of studies focusing on remission from PEs and improvement of other non-psychotic clinical and functional outcomes suggests a need for further research into psychological treatments for this population.
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